1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor : a single- and multiple-dose first-in-human study in healthy participants
(
- Contribution to journal › Article
- 2019
-
Mark
Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors : a phase 2, multicenter study
(
- Contribution to journal › Article
- 2015
-
Mark
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity
(
- Contribution to journal › Article
- 2014
-
Mark
A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
(
- Contribution to journal › Article
- 2012
-
Mark
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination
(
- Contribution to journal › Article
- 2008
-
Mark
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia
(
- Contribution to journal › Article
- 2006
-
Mark
Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
(
- Contribution to journal › Article
- 2003
-
Mark
High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
(
- Contribution to journal › Article
- 1996
-
Mark
Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus
(
- Contribution to journal › Article